ArticleBMC genetics2015
Genetic polymorphisms of pharmacogenomic VIP variants in the Uygur population from northwestern China.
Article in BMC genetics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Genetic diversity of variants involved in drug response among Tunisian and Italian populations toward personalized medicine.Scientific reports · 2024Article
- Genetic analysis of pharmacogenomic VIP variants in the Wa population from Yunnan Province of China.BMC genomic data · 2021Article
- Genetic variation of pharmacogenomic VIP variants in Zhuang nationality of southern China.The pharmacogenomics journal · 2021Article
- Population Genetic Difference of Pharmacogenomic VIP Variants in the Tibetan Population.Pharmacogenomics and personalized medicine · 2021Article
- Genetic Polymorphisms of Pharmacogenes among the Genetically Isolated Circassian Subpopulation from Jordan.Journal of personalized medicine · 2020Article
- Population genetic difference of pharmacogenomic VIP gene variants in the Lisu population from Yunnan Province.Medicine · 2018Article
- Genetic polymorphisms of pharmacogenomic VIP variants in the Lisu population of southwestern China: A cohort study.Medicine · 2018Observational
- Article
- Pharmacogenetic landscape of Metabolic Syndrome components drug response in Tunisia and comparison with worldwide populations.PloS one · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDrug response variability observed amongst patients is caused by the interaction of both genetic and non-genetic factors, and frequencies of functional genetic variants are known to vary amongst populations. Pharmacogenomic research has the potential to help with individualized treatments. We have not found any pharmacogenomics information regarding Uygur ethnic group in northwest China. In the present study, we genotyped 85 very important pharmacogenetic (VIP) variants (selected from the PharmGKB database) in the Uygur population and compared our data with other eleven populations from the HapMap data set.
resultsThrough statistical analysis, we found that CYP3A5 rs776746, VKORC1 rs9934438, and VKORC1 rs7294 were most different in Uygur compared with most of the eleven populations from the HapMap data set. Compared with East Asia populations, allele A of rs776746 is less frequent and allele A of rs7294 is more frequent in the Uygur population. The analysis of F-statistics (Fst) and population structure shows that the genetic background of Uygur is relatively close to that of MEX.
conclusionsOur results show significant differences amongst Chinese populations that will help clinicians triage patients for better individualized treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.